Modification of menopausal hormone therapy-associated colorectal cancer risk by polymorphisms in sex steroid signaling, metabolism and transport related genes

Endocrine-Related Cancer

Volumn 18, Issue 3, 2011, Pages 371-384

  Rudolph, Anja ^a   Sainz, Juan ^a   Hein, Rebecca ^a   Hoffmeister, Michael ^a   Frank, Bernd ^a   Försti, Asta ^a,b   Brenner, Hermann ^a   Hemminki, Kari ^a,b   Chang Claude, Jenny ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Clinical Research Center   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 17; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GLUTATHIONE TRANSFERASE P1; MULTIDRUG RESISTANCE PROTEIN 1; PREGNANE X RECEPTOR; PROGESTERONE RECEPTOR; SEX HORMONE BINDING GLOBULIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ESTROGEN METABOLISM; FEMALE; GENOTYPE; HOMOZYGOTE; HORMONE SUBSTITUTION; HORMONE TRANSPORT; HUMAN; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; RISK REDUCTION; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; CARCINOMA; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; GENETIC ASSOCIATION STUDIES; GONADAL STEROID HORMONES; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 79960083210     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0057     Document Type: Article

References (69)

1. Agoulnik IU, Tong XW, Fischer DC, Korner K, Atkinson NE, Edwards DP, Headon DR, Weigel NL & Kieback DG 2004 A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. Journal of Clinical Endocrinology and Metabolism 89 6340-6347. (doi:10.1210/jc.2004-0114)
2. Ascenzi P, Bocedi A & Marino M 2006 Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Molecular Aspects of Medicine 27 299-402. (doi:10.1016/j.mam.2006.07.001)
3. Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Gilbert M, Hamann U & Scott RJ 2009 Estrogen receptor polymorphisms and the risk of endometrial cancer. BJOG : an International Journal of Obstetrics and Gynaecology 116 1053-1061. (doi:10.1111/j.1471-0528.2009.02185.x)
4. Barnes KM, Dickstein B, Cutler GB Jr, Fojo T & Bates SE 1996 Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 35 4820-4827. (doi:10.1021/bi952380k)
5. Barrett JC, Fry B, Maller J & Daly MJ 2005 Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 263-265. (doi:10.1093/bioinformatics/bth457)
6. Bartsch H, Nair U, Risch A, Rojas M, Wikman H & Alexandrov K 2000 Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiology, Biomarkers & Prevention 9 3-28. (Pubitemid 30062906)
7. Bebawy M & Chetty M 2009 Gender differences in P-glycoprotein expression and function: effects on drug disposition and outcome. Current Drug Metabolism 10 322-328. (doi:10.2174/138920009788498996)
8. Beral V, Banks E & Reeves G 2002 Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360 942-944. (doi:10.1016/S0140-6736(02)11032-4)
9. Berggren S, Gall C, Wollnitz N, Ekelund M, Karlbom U, Hoogstraate J, Schrenk D & Lennernas H 2007 Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Molecular Pharmacology 4 252-257. (doi:10.1021/mp0600687)
10. Brenner H, Chang-Claude J, Seiler CM, Sturmer T & Hoffmeister M 2006 Does a negative screening colonoscopy ever need to be repeated? Gut 55 1145-1150. (doi:10.1136/gut.2005.087130)
11. Brenner H, Chang-Claude J, Seiler CM, Rickert A & Hoffmeister M 2011 Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Annals of Internal Medicine 154 22-30.
12. Brinkmann U & Eichelbaum M 2001 Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics Journal 1 59-64. (doi:10.1038/sj.tpj. 6500001)
13. Chen GG, Zeng Q & Tse GM 2008 Estrogen and its receptors in cancer. Medicinal Research Reviews 28 954-974. (doi:10.1002/med.20131)
14. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C et al. 2004 Estrogen plus progestin and colorectal cancer in postmenopausal women. New England Journal of Medicine 350 991-1004. (doi:10.1056/NEJMoa032071)
15. Cho NL, Javid SH, Carothers AM, Redston M & Bertagnolli MM2007 Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Research 67 2366-2372. (doi:10.1158/0008-5472.CAN-06-3026)
16. Cousin P, Dechaud H, Grenot C, Lejeune H & Pugeat M 1998 Human variant sex hormone-binding globulin (SHBG) with an additional carbohydrate chain has a reduced clearance rate in rabbit. Journal of Clinical Endocrinology and Metabolism 83 235-240. (doi:10.1210/jc.83.1.235)
17. Dawling S, Roodi N, Mernaugh RL, Wang X & Parl FF 2001 Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Research 61 6716-6722. (Pubitemid 32896493)
18. Delaunay F, Pettersson K, Tujague M & Gustafsson JA 2000 Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Molecular Pharmacology 58 584-590.
19. De Vivo I, Huggins GS, Hankinson SE, Lescault PJ, Boezen M, Colditz GA & Hunter DJ 2002 A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. PNAS 99 12263-12268. (doi:10.1073/pnas.192172299)
20. Dudley EC, Hopper JL, Taffe J, Guthrie JR, Burger HG & Dennerstein L 1998 Using longitudinal data to define the perimenopause by menstrual cycle characteristics. Climacteric 1 18-25. (doi:10.3109/13697139809080677)
21. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O & Rice LW 2000 Selective loss of estrogen receptor beta in malignant human colon. Cancer Research 60 245-248. (Pubitemid 30070743)
22. Frohlich M, Albermann N, Sauer A, Walter-Sack I, Haefeli WE & Weiss J 2004 In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochemical Pharmacology 68 2409-2416. (doi:10.1016/j.bcp.2004.08. 026)
23. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M et al. 2002 The structure of haplotype blocks in the human genome. Science 296 2225-2229. (doi:10.1126/science.1069424)
24. Gutmann DA, Ward A, Urbatsch IL, Chang G & van Veen HW 2010 Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1. Trends in Biochemical Science 35 36-42. (doi:10.1016/j.tibs.2009. 07.009)
25. Hamilton KO, Yazdanian MA & Audus KL 2001 Modulation of P-glycoprotein activity in Calu-3 cells using steroids and beta-ligands. International Journal of Pharmaceutics 228 171-179. (doi:10.1016/S0378-5173(01) 00836-5)
26. Hanna IH, Dawling S, Roodi N, Guengerich FP & Parl FF 2000 Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Research 60 3440-3444. (Pubitemid 30482162)
27. Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, Strom A & Gustafsson JA 2009 Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Research 69 6100-6106. (doi:10.1158/0008-5472.CAN- 09-0506)
28. Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Meyers DA et al. 2002 Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 105 1879-1882. (doi:10.1161/01.CIR. 0000016173.98826.88)
29. Hildebrand JS, Jacobs EJ, Campbell PT, McCullough ML, Teras LR, Thun MJ & Gapstur SM 2009 Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II. Cancer Epidemiology, Biomarkers & Prevention 18 2835-2841. (doi:10.1158/1055-9965. EPI-09-0596)
30. Ho GT, Moodie FM & Satsangi J 2003 Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 52 759-766. (doi:10.1136/gut.52.5.759)
31. Hoffmeister M, Raum E, Winter J, Chang-Claude J & Brenner H 2007 Hormone replacement therapy, body mass, and the risk of colorectal cancer among postmenopausal women from Germany. British Journal of Cancer 97 1486-1492. (doi:10.1038/sj.bjc.6604066)
32. Hoffmeister M, Raum E, Krtschil A, Chang-Claude J & Brenner H 2009 No evidence for variation in colorectal cancer risk associated with different types of postmenopausal hormone therapy. Clinical Pharmacology and Therapeutics 86 416-424. (doi:10.1038/clpt.2009.134)
33. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M et al. 2000 Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. PNAS 97 3473-3478. (doi:10.1073/pnas.050585397)
34. Hsu HH, Cheng SF, Chen LM, Liu JY, Chu CH, Weng YJ, Li ZY, Lin CS, Lee SD, Kuo WW et al. 2006 Overexpressed estrogen receptor-alpha up-regulates hTNF-alpha gene expression and down-regulates beta-catenin signaling activity to induce the apoptosis and inhibit proliferation of LoVo colon cancer cells. Molecular and Cellular Biochemistry 289 101-109. (doi:10.1007/s11010-006-9153-3)
35. Hu X, O'Donnell R, Srivastava SK, Xia H, Zimniak P, Nanduri B, Bleicher RJ, Awasthi S, Awasthi YC, Ji X et al. 1997 Active site architecture of polymorphic forms of human glutathione S-transferase P1-1 accounts for their enantioselectivity and disparate activity in the glutathione conjugation of 7beta,8alpha-dihydroxy-9alpha,10alpha-ox y-7,8,9,10-tetrahydrobenzo(a)pyrene. Biochemical and Biophysical Research Communications 235 424-428. (doi:10.1006/bbrc.1997.6777)
36. Jassam N, Bell SM, Speirs V & Quirke P 2005 Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes' staging. Oncology Reports 14 17-21.
37. Kabat GC, Miller AB & Rohan TE 2008 Oral contraceptive use, hormone replacement therapy, reproductive history and risk of colorectal cancer in women. International Journal of Cancer 122 643-646. (doi:10.1002/ijc.23079)
38. Kennelly R, Kavanagh DO, Hogan AM & Winter DC 2008 Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncology 9 385-391. (doi:10.1016/S1470-2045(08)70100-1)
39. Kim WY & Benet LZ 2004 P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharmaceutical Research 21 1284-1293. (doi:10.1023/B:PHAM.0000033017.52484.81)
40. King BP, Khan TI, Aithal GP, Kamali F & Daly AK 2004 Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 14 813-822. (doi:10.1097/00008571-200412000-00004)
41. Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, Sotiropoulou-Bonikou G & Papavassiliou AG 2003 Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. European Journal of Cancer 39 1251-1258. (doi:10.1016/S0959-8049(03)00239-9)
42. Koo JH & Leong RW 2010 Sex differences in epidemiological, clinical and pathological characteristics of colorectal cancer. Journal of Gastroenterology and Hepatology 25 33-42. (doi:10.1111/j.1440-1746.2009.05992.x)
43. La Vecchia C, Gallus S & Fernandez E 2005 Hormone replacement therapy and colorectal cancer: an update. Journal of the British Menopause Society 11 166-172. (doi:10.1258/136218005775544264)
44. Lilla C, Verla-Tebit E, Risch A, Jager B, Hoffmeister M, Brenner H & Chang-Claude J 2006 Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer Epidemiology, Biomarkers & Prevention 15 99-107. (doi:10.1158/1055- 9965.EPI-05-0618)
45. Lin J, Zee RY, Liu KY, Zhang SM, Lee IM, Manson JE, Giovannucci E, Buring JE & Cook NR 2010 Genetic variation in sex-steroid receptors and synthesizing enzymes and colorectal cancer risk in women. Cancer Causes & Control 21 897-908. (doi:10.1007/s10552-010-9518-5)
46. Lindstrom S, Yen YC, Spiegelman D & Kraft P 2009 The impact of gene-environment dependence and misclassification in genetic association studies incorporating gene-environment interactions. Human Heredity 68 171-181. (doi:10.1159/000224637)
47. MARIE-GENICA-Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk 2010a Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy. International Journal of Cancer 126 2935-2946. (doi:10.1002/ijc.24892)
48. MARIE-GENICA-Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk 2010b Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1-K34-T>C polymorphism. Breast Cancer Research and Treatment 120 737-744. (doi:10.1007/s10549-009-0490-2)
49. McInerney EM, Weis KE, Sun J, Mosselman S & Katzenellenbogen BS 1998 Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology 139 4513-4522. (doi:10.1210/en.139.11.4513)
50. Morimoto LM, White E & Newcomb PA 2003 Selection bias in the assessment of gene-environment interaction in case-control studies. American Journal of Epidemiology 158 259-263. (doi:10.1093/aje/kwg147)
51. Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K & Sugimoto Y 2006 Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Science 97 1198-1204. (doi:10.1111/j.1349-7006.2006.00300.x)
52. Nebert DW & Russell DW 2002 Clinical importance of the cytochromes P450. Lancet 360 1155-1162. (doi:10.1016/S0140-6736(02)11203-7)
53. Pearce CL, Near AM, Van Den Berg DJ, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Anderson AR, Edlund CK, Wu AH et al. 2009 Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. British Journal of Cancer 100 412-420. (doi:10.1038/sj.bjc.6604820)
54. Roediger WE & Babidge W 1997 Human colonocyte detoxification. Gut 41 731-734. (doi:10.1136/gut.41.6.731)
55. Sachse C, Brockmoller J, Bauer S & Roots I 1999 Functional significance of a C → A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. British Journal of Clinical Pharmacology 47 445-449. (doi:10.1046/j.1365-2125.1999.00898.x)
56. Schuit SC, Oei HH, Witteman JC, Geurts van Kessel CH, van Meurs JB, Nijhuis RL, van Leeuwen JP, de Jong FH, Zillikens MC, Hofman A et al. 2004 Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. Journal of the American Medical Association 291 2969-2977. (doi:10.1001/jama. 291.24.2969)
57. Setiawan VW, Hankinson SE, Colditz GA, Hunter DJ & De Vivo I 2004 HSD17B1 gene polymorphisms and risk of endometrial and breast cancer. Cancer Epidemiology, Biomarkers & Prevention 13 213-219. (doi:10.1158/1055-9965. EPI-03-0241)
58. Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM & Inoue K 1999 Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20 1607-1613. (doi:10.1093/carcin/20.8.1607)
59. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L & Ingelman-Sundberg M 2006 A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clinical Pharmacology and Therapeutics 79 103-113. (doi:10.1016/j.clpt.2005.10.002)
60. Slattery ML, Sweeney C, Murtaugh M, Ma KN, Wolff RK, Potter JD, Caan BJ & Samowitz W 2005 Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiology, Biomarkers & Prevention 14 2936-2942. (doi:10.1158/1055-9965.EPI-05-0514)
61. Soranzo N, Cavalleri GL, Weale ME, Wood NW, Depondt C, Marguerie R, Sisodiya SM & Goldstein DB 2004 Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. Genome Research 14 1333-1344. (doi:10.1101/gr.1965304)
62. Srivastava SK, Singhal SS, Hu X, Awasthi YC, Zimniak P & Singh SV 1999 Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Archives of Biochemistry and Biophysics 366 89-94. (doi:10.1006/abbi.1999.1217)
63. Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M & Dahiya R 2003 Polymorphisms of estrogen receptor alpha in prostate cancer. Molecular Carcinogenesis 37 202-208. (doi:10.1002/mc.10138)
64. Tsilidis KK, Allen NE, Key TJ, Sanjoaquin MA, Bakken K, Berrino F, Fournier A, Lund E, Overvad K, Olsen A et al. 2010 Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer 128 1881-1889. (doi:10.1002/ijc.25504)
65. Wedlund PJ 2000 The CYP2C19 enzyme polymorphism. Pharmacology 61 174-183. (doi:10.1159/000028398)
66. Wilkins HR, Doucet K, Duke V, Morra A & Johnson N 2010 Estrogen prevents sustained COLO-205 human colon cancer cell growth by inducing apoptosis, decreasing c-myb protein, and decreasing transcription of the antiapoptotic protein bcl-2. Tumour Biology 31 16-22. (doi:10.1007/s13277-009- 0003-2)
67. Xita N & Tsatsoulis A 2010 Genetic variants of sex hormone-binding globulin and their biological consequences. Molecular and Cellular Endocrinology 316 60-65. (doi:10.1016/j.mce.2009.08.025)
68. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C et al. 2001 The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11 555-572. (doi:10.1097/00008571-200110000-00003)
69. Zheng SL, Zheng W, Chang BL, Shu XO, Cai Q, Yu H, Dai Q, Xu J & Gao YT 2003 Joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women. Cancer Research 63 7624-7629. (Pubitemid 37466685)